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Abstract.		
Recent	advances	in	the	use	of	radiometals	for	both	imaging	and	therapy	has	spurred	on	the	
development	 of	 an	 original	 chemistry	 that	 endows	 radionuclide-chelating	molecular	 cages	
with	ever	sharper	physicochemical	properties.	Macrocyclic	polyamines	(MPAs)	such	as	cyclen	
and	 DOTA	 are	 among	 the	 most	 frequently	 encountered	 cages	 for	 the	 design	 of	 new	
radiotracers,	 owing	 to	 their	 versatile	 chemistry	 that	 makes	 them	 customizable	 molecular	
tools.	 The	 idea	of	using	MPAs	 for	alternative	purposes	has	 recently	emerged,	with	an	eye	
towards	 benefiting	 from	 their	 unique	 topology,	 versatility,	 symmetry	 and	water-solubility.	
This	review	summarizes	strategies	that	have	been	recently	implemented	in	which	MPAs	are	
used	as	multivalent	molecular	platforms	for	constructing	sophisticated	suprastructures	that	
found	 applications	 in	 various	 fields,	 from	 material	 chemistry	 to	 chemical	 biology.	 These	
original	approaches	are	invaluable	in	that	they	successfully	expand	the	scope	of	applications	
of	MPAs	far	beyond	their	restricted	roles	of	metal	chelating	appendages.		
	
Keywords:	 polyazamacrocycles;	 molecular	 platform;	 multivalency;	 theranostics;	 bioactive	
compounds	
	
	
Introduction	
Chemistry	is	the	art	of	playing	with	complex	molecular	scaffolds	to	diversify	their	uses	in	a	
creative	and	virtually	unlimited	manner.	The	capability	of	chemists	to	modulate	ad	libitum	the	
nature	of	chemical	objects	allows	them	for	optimizing	the	properties	of	selected	compounds	
for	 intended	 purposes	 (e.g.,	 structure-activity	 relationship	 studies)	 or	 endowing	 chemicals	
with	new	functions,	thereby	opening	new	scopes	and	fields	of	application.	Many	examples	of	
the	latter	approach	can	be	cited,	including	the	chemical	modification	of	natural	nutrients	for	
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cancer-directed	applications,	owing	to	the	known	avidity	of	malignant	cells:	for	instance,	the	
modification	of	glucose	into	2-deoxy-2-[fluorine-18]fluoro-glucose	(18FDG)	allows	its	use	as	an	
effective	probe	for	imaging	various	cancers	via	positron	emission	tomography	integrated	with	
computed	tomography	(PET/CT);[1]	also,	the	repurposing	of	vitamin	B9	(folic	acid)	as	a	cancer-
specific	 carrier	 of	 drugs	 (e.g.,	 maytansine,	 camptothecin)	 was	 thoroughly	 exploited	 in	 an	
approach	referred	to	as	small-molecule	drugs	conjugates	(SMDCs).[2]	In	fewer	cases,	chemists	
have	also	strived	to	repurpose	fully	synthetic	compounds	initially	designed	to	fulfill	precisely	
defined	 tasks,	 to	 open	 new	 chemical	 landscapes.	 In	 the	 present	 review,	we	 focus	 on	 the	
example	of	macrocyclic	polyamines	(MPAs),[3]	which	comprise	a	class	of	nitrogen-containing	
heterocyclic	 compounds	 that	 have	 found	many	 applications	 in	medicinal	 chemistry.[4]	 The	
most	 emblematic	MPA	 is	 certainly	 the	 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic	
acid	(or	DOTA)	(Figure	1).[5]	This	macrocycle	has	been	thoroughly	exploited	for	its	ability	to	
firmly	 chelate	metal	 ions,	 thanks	 of	 the	 presence	 of	 4	 nitrogen	 atoms	 (embedded	 in	 the	
macrocyclic	structure)	and	4	surrounding	carboxylic	moieties	(belonging	to	 its	4	acetic	acid	
pendant	arms).	This	eightfold	valency	has	made	DOTA	and	DOTA-like	molecules	 invaluable	
tools	 for	 multiple	 applications	 such	 as	 waste-water	 treatment,	 hydrometallurgy,	 and	
medicine.[3a]	In	the	medical	field,	the	use	of	metal	complexes	of	DOTA	is	closely	connected	to	
molecular	 imaging	 and,	 increasingly,	 to	 internal	 radiation	 therapy,	 or	 radioendotherapy.	
Gadolinium(III)	complexes	of	DOTA	and	similar	macrocyclic	chelators	are	the	perfect	example	
of	successful	inorganic	drugs	that	have	become	commonplace	in	medicinal	practice	in	the	last	
decade.	Thanks	to	their	high	relaxitivity	and	stability	in	physiological	media,	they	have	become	
the	 gold	 standard	 contrast	 agents	 for	 magnetic	 resonance	 imaging	 (MRI).[6]	 However,	
gadolinium-based	contrast	agents	used	in	the	clinic	are	not	disease-specific;	as	a	matter	of	
fact,	 the	 clear	 delineation	 of	 soft	 tissues	 they	 provide	 relies	 on	 their	 wide,	 non-specific,	
distribution	in	the	body	that	requires	the	use	of	large	amounts	of	metallic	complex.	In	sharp	
contrast,	DOTA-metal	complexes	can	also	be	used	for	specific	detection	of	diseases	with	trace	
amounts	of	 imaging	agent.	 In	 a	 classical	 approach,	DOTA	and	DOTA-like	molecules	 can	be	
conjugated	to	biological	vectors	of	interest	(peptides,	proteins,	antibodies)	prior	to	chelating	
a	 radiometal	 of	 interest	 (e.g.,	 gallium-68,	 indium-111,	 yttrium-90,	 lutetium-177).[7]	 The	
resulting,	highly	thermodynamically	stable	complexes	can	thus	be	used	in	vivo	for	diagnosis,	
via	 the	use	of	a	broad	variety	of	 imaging	modalities	 (positron	emission	 tomography	 (PET),	
single	photon	emission	computed	tomography	(SPECT),	Cerenkov	luminescence	imaging	(CLI),	
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etc.),	multimodality	approaches,[8]	or	therapeutic	purposes,	through	radioendotherapy	using	
electron	 (b-	 decay)-	 or	 alpha	 (a)-particle	 emitting	 radiometals,	 or	 both	 (the	 so-called	
theranostic	approach).[9]	The	unique	complexation	properties	of	DOTA	and,	beyond	this,	of	
many	MPAs,	and	their	medical	uses	thereof,	are	regularly	covered	by	authoritative	reviews	
the	reader	is	invited	to	refer	to.[3a,	4,	6,	8,	10]		
	
	
Figure	1.	Schematic	representation	of	the	uses	of	DOTA	either	as	molecular	cage	for	chelating	metals	(left	panel)	
or	as	platform	to	assemble	multivalent	molecular	tools	(right	panel),	which	is	the	key	topic	of	the	review.		
	
Here,	we	focus	on	original	strategies	that	have	been	devised	and	implemented	over	the	
past	few	years	to	exploit	another,	lesser-known	aspect	of	MPAs,	unrelated	to	metal	chelation.	
DOTA	encodes	an	interesting	topological	information,	due	to	the	programmable	positioning	
of	 its	 four,	 easily	 derivatizable	 acetic	 acid	 arms,	 which	 has	 not	 received	 the	 attention	 it	
deserves.	 Beyond	 its	 chemical	 stability,	 inherent	 polarity	 and	 marked	 aqueous	 solubility,	
DOTA	can	be	used	as	a	molecular	platform	to	allow	for	assembling	up	to	four	compounds	of	
interest	 in	a	 single	 scaffold,	 and	possibly	modulate	 the	physico-chemical	properties	of	 the	
resulting	multi-component	molecular	 architecture	 (Figure	1).	 This	 approach	has	 led	 to	 the	
design,	 synthesis	 and	 studies	 of	 original,	 highly	 functionalized	MPAs,	which	 can	 be	 either	
symmetrical	(fourfold	derivatization)	or	not	(tailored	derivatization	for	endowing	MPAs	with	
multiple	 distinct	molecular	 fragments	 and	 functionalities).	 As	 further	 detailed	 in	 the	 next	
sections,	these	exquisite	molecular	tools	have	found	applications	in	various	chemical	fields,	
from	soft	matter	 to	chemical	biology.	This	 review	 is	not	mainly	dedicated	 to	 the	synthetic	
aspects	related	to	MPAs	since	the	vast	majority	of	molecular	tools	showed	below	are	readily	
prepared	 through	 conventional	N-alkylation	 and/or	 peptide-like	 coupling	 reactions,	 taking	
advantage	of	well-established	protecting	group	manipulations.	HPLC	purifications	are	often	
privileged	 for	 their	 isolation	 in	 pure	 form	 (often	 as	 trifluoroacetic	 acid	 salts),	 due	 to	 the	
marked	 polarity	 and	 large	 molecular	 size	 of	 these	 sophisticated	 multivalent	 conjugates.	
Nevertheless,	for	some	examples	of	functionalized	MPAs,	more	specific	information	related	
to	their	synthesis/purification	which	we	consider	to	be	relevant	for	the	reader	will	be	provided	
throughout	the	text.		
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1.	Symmetrical	MPAs	
Full-N-functionalization	 of	 readily	 available	 tetraazacycloalkanes	 (i.e.,	 cyclam,	 cyclen	 and	
TACN,	 vide	 infra)	 with	 the	 same	 molecular	 arm	 may	 be	 regarded	 as	 one	 of	 the	 most	
straightforward	and	simple	way	to	access	to	multivalent	compounds	with	specific	structural	
features	and	 tailored	properties.	 It	 is	 therefore	not	 surprising	 that	 the	 first	applications	of	
MPAs	beyond	metal	chelation	were	based	on	use	of	such	symmetrical	architectures.		
	
1.1	Soft	matter	and	chirality	sensing	
In	the	early	2000s,	Michinobu,	Tsukube	and	co-workers	have	synthesized	a	DOTA	conjugated	
to	 four	 chiral	 cholesterol	 units	 (one	 per	 arm),	 through	 tetra-N-alkylation	 of	 1,4,7,10-
tetraazacyclododecane	 (or	 cyclen)	 with	 cholesterol	 chloroacetate	 (1,	 Figure	 2).[11]	 This	
derivative	self-assembles	in	aqueous	ethanol	solutions	(20-30%)	as	chiral	aggregates	(critical	
aggregation	concentration:	4	µM),	due	to	the	intrinsic	chirality	of	the	cholesterol	unit	that	is	
spread	over	the	whole	supramolecular	structure	upon	self-association.		
	
	
	
Figure	2.	Structure	of	the	cholesterol-armed	cyclen	designed	by	Michinobu,	Tsukube	and	co-workers.	Formation	
of	 its	 octadentate	Na+	 complex	 and	 subsequent	 self-assembly	 to	 chiral	 host	monolayer	 (at	 the	 interface	 air-
water)	for	mechanical	control	of	enantioselectivity	of	amino	acid	recognition.	
	
This	 asymmetry	 was	 exploited	 to	 sense	 amino	 acids	 fluorescently	 labeled	 with	 an	
environment-sensitive	 fluorophore,	 namely	 dansyl,	 in	 solution,	 discriminating	 for	 instance	
between	 dansyl-L-leucine	 and	 dansyl-D-leucine	 by	 both	 the	 fluorescence	 enhancements	
(triggered	by	the	hydrophobic	pocket	provided	by	the	cholesterol	units,	6.5-	versus	4.9-fold,	
respectively,	i.e.,	1.3-fold	difference)	and	the	blue-shifts	of	emission	maxima	(from	532	to	505	
and	507	nm,	respectively).[12]	Furthermore,	at	the	air-water	interface,	compound	1	leads	to	
the	formation	of	a	stable	monolayer	(molecular	area:	1.6	nm2;	collapse	pressure:	50	mM.m-1),	
owing	to	its	resolutely	amphiphilic	nature	(hydrophobic	cholesterol	versus	hydrophilic	MPA	
on	the	other	hand)	(Figure	2).	The	resulting	chiral	monolayer	was	exploited	to	sense	unlabeled	
amino	acids,	discriminating	L-leucine	versus	D-leucine	by	their	binding	constants	(K)	measured	
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via	surface	pressure	(p-A)	isotherm	measurements	(K	=	85.2	versus	1063.0	M-1,	respectively,	
i.e.,	 12.5-fold	 difference	 at	 1	 mM.m-1	 pressure).[13]	 Of	 note,	 in	 these	 investigations,	 the	
presence	of	Na+	 ion	 is	mandatory,	as	a	 trigger	 for	 the	chiral	 folding	 the	cholesterol-armed	
DOTA	via	its	octacoordination	at	the	very	heart	of	the	conjugate.		
	
1.2	Medicinal	chemistry	and	multivalency	
A	possible	way	to	 improve	the	efficiency	of	 therapeutics	 is	 to	assemble	multiple	units	 in	a	
same	 scaffold	 (the	 so-called	multivalency	 approach)[14]	 via	 covalent	 linking	 to	 a	molecular	
platform.	 Recent	 studies	 seem	 to	 indicate	 that	 ligand	 hetero-	 or	 homo-multimerization	
provides	increase	in	half-life	in	vivo,	circulation	time	and	receptor	avidity.	Thorough	studies	
were	 performed	 with	 cyclic	 arginine-glycine-aspartic	 acid	 (RGD)	 peptides	 c(RGDfK)	 or	
c(RGDyK),	which	targets	integrin	αvβ3,[15]	among	others.	This	receptor	affects	tumor	growth,	
local	 invasiveness,	 metastatic	 potential	 and	 is	 lowly	 expressed	 on	 the	 surface	 of	 non-
malignant	 cells	while	being	overexpressed	on	 tumor	 cells	 in	need	of	neovasculature.	 Such	
expression	 profile	 constitutes	 a	 unique	 therapeutic	 target.[16]	 Furthermore,	 it	 has	 been	
demonstrated	 that	 integrin	 heterodimers	 are	 prone	 to	 receptor	 clustering	 upon	 cell	
activation,	 resulting	 in	 increased	 ligand	 avidity.[17]	 Thus,	 strategies	 of	 multimerization	 of	
c(RGDfK)	have	already	been	implemented	successfully,	mostly	through	the	use	of	trifunctional	
amino	acid-based	platforms.	As	an	example,	the	glutamic	acid	(E)	was	used	to	synthesize	both	
the	dimer	E[c(RGDfK)]2	and	the	tetramer	E[E[c(RGDfK)]2]2	(in	which	two	dimers	are	linked	via	
an	additional	glutamic	acid	unit).[18]	Both	derivatives	show	improved	integrin	binding	affinity	
and	 cellular	 uptake,	 lending	 credence	 to	 this	 strategy.	 Similarly,	 Boturyn	 and	 co-workers	
reported	on	the	synthesis	of	a	Cy5.0-labeled	c(RGDfK)	tetramer	based	on	a	cyclic	decapeptide	
scaffold	(RAFT)	that	displayed	improved	selectivity	for	tumor	xenografts	overexpressing	the	
αvβ3	 receptor	 in	 comparison	 with	 its	 monomeric	 counterpart.[19]	 	 Cheng	 and	 co-workers	
further	 explored	 it,	 exploiting	 the	 unique	 versatility	 of	 the	 DOTA	 platform	 to	 construct	
monomeric	to	tetrameric	c(RGDfK)	conjugates	(DOTA-P1,	-P2,	-P3	and	-P4,	respectively,	with	
P	for	peptide)	(Figure	3).[20]	Of	note,	the	easy-to-implement	synthetic	protocol	described	here,	
based	on	the	aminolysis	of	N-hydroxysulfosuccinimidyl	ester	of	DOTA	(DOTA-sulfo-NHS)	by	
fully	 deprotected	 peptide	 c(RGDyK)	 in	 aqueous	 buffer,	was	 devised	 to	 rapidly	 obtain	 RGD	
multimers.	The	four	compounds	were	obtained	during	a	single	coupling	reaction	conducted	
with	a	large	excess	of	DOTA-sulfo-NHS,	and	recovered	in	a	pure	form	by	reversed-phase	HPLC	
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purification,	but	neither	in	large	amounts	nor	in	optimized	yields.	This	study	confirmed	the	
better	integrin	affinity	of	DOTA-Ps,	evaluated	through	competitive	binding	assays	against	125I-
echistatin	 (IC50	 =	 380,	 37	 and	 13	 nM	 for	 DOTA-P1,	 -P2	 and	 -P3,	 respectively),	 but	 also	
highlighted	that	the	DOTA	tetra-functionalization	might	be	chemically	challenging	especially	
via	amidation	reactions	performed	in	aqueous	buffer	(pH	8.5-9.0),	given	that	DOTA-P4	was	
not	isolated	in	quantities	suited	to	in	vitro	evaluations.	
	
	
Figure	3.	Selected	examples	of	macrocyclic	chelator-assembled	RGD	(upper	panel)	and	KuE	(center,	lower	panel)	
multimers	for	tumor	targeting	through	PET	imaging,	as	well	as	merged	DOTA	and	RGD	scaffold	(both	sides,	lower	
panel).	Counter-ions	(mostly	TFA)	not	shown.	
	
A	 further	 step	was	 taken	 towards	 the	 optimization	 of	 the	 chemical	 nature	 of	 DOTA/RGD	
conjugates	 by	 Sun,	 Leon-Rodriguez	 and	 co-workers,	 merging	 the	 DOTA	 and	 RGD/RGDf	
structures	 in	 a	 single	 scaffold,	 with	 the	 hope	 of	 decreasing	 conformational	 variability.[21]	
However,	 the	 resulting	cyclic	c(DOTA-RGD)	and	 c(DOTA-RGDf)	 (Figure	3)	displayed	no	 real	
improvements,	with	a	lower	avb3	binding	in	vitro	than	the	RGD	control	(IC50	=	4.7	and	20.4	nM	
for	c(DOTA-RGD)	and	c(DOTA-RGDf),	respectively	versus	6.7	nM	for	RGDf)	and	lower	tumor	
uptake	 in	 vivo	 (when	 labelled	 with	 177Lu	 and	 64Cu).	 Notni	 and	 co-workers	 developed	 an	
alternative	strategy	to	tackle	DOTA	derivatization	issues,	replacing	the	DOTA	platform	by	the	
more	 reactive	 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphinic	 acid	
(DOTPI).	The	tetra-functionalization	of	DOTPI	was	performed	through	the	sequential	coupling	
of	 amino	 acid	 PEG4	 linkers	 (DOTPI(PEG4)4,	 isolated	 yield	 =	 38%)	 and	 fully	 protected	
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c(RGDfK)(Pbf,tBu)	 peptide	 followed	 by	 TFA	 treatment	 to	 remove	 protecting	 groups	
(DOTPI(RGD)4,	isolated	yield	=	68%)	(Figure	3).[22]	The	use	of	the	peptide	coupling	reagent	O-
(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium	 hexafluorophosphate	 (HATU)	 allows	
for	 achieving	 chemoselective	 amidation	 reactions	 without	 protection	 of	 the	 phosphinate	
moieties,	making	the	synthesis	of	DOTPI(RGD)4	particularly	straightforward.	This	conjugate	
displayed	a	higher	integrin	affinity,	evaluated	by	ELISA	using	cilengitide	as	internal	standard,	
with	IC50	=	1330	and	109	pM	for	monomeric	c(RGDfK)	and	DOTPI(RGD)4,	respectively	(i.e.,	
12.2-fold	difference).	The	same	research	group	also	explored	the	grafting	of	 four	prostate-
specific	membrane	antigen	(PSMA)	inhibitors	KuE	(Lys-urea-Glu)	to	DOTPI	platform	via	click	
chemistry	(both	copper-catalyzed	and	copper-free	azide-alkyne	cycloadditions,	CuAAC[23]	and	
SPAAC,[24]	respectively,	to	assess	whether	Cu(II)	precatalyst	can	be	used	or	not	in	the	context	
of	molecular	platform	with	marked	copper	chelating	ability).	PSMA,	being	a	membrane-bound	
zinc	hydrolase	overexpressed	in	prostate	cancers,	is	a	high-value	target	(being	subjected	to	
190	clinical	trials,	23	of	them	being	currently	active).[25]	Obtained	multimers	DOTPI(Trz-KuE)4	
and	DOTPI(DBCO-KuE)4	 (Trz	for	triazole,	DBCO	for	dibenzocyclooctyne)	(Figure	3)	display	a	
higher	 PSMA	 affinity	 than	 monomeric	 KuE,	 along	 with	 high	 tumor	 uptake	 and	 blood	
clearance.[26]	Of	note,	in	these	investigations,	radiometals	were	subsequently	sequestered	at	
the	 very	 heart	 of	 both	 DOTA-Ps	 and	 DOTPIs	 to	 allow	 for	 tracking	 biodistribution	 of	 the	
resulting	complexes	in	vivo	through	nuclear	imaging.		
	
1.3	Chemical	genetics	and	biomimicry	
The	fourfold	symmetry	of	DOTA	was	also	exploited	for	the	construction	of	chemicals	targeting	
fourfold	 symmetrical	 targets.	 Quadruplex-DNA	 and	 RNA	 (or	 G4-DNA	 and	 G4-RNA,	
respectively)	fold	from	guanine	(G)-rich	nucleic	acid	sequences.[27]	The	structure	of	this	higher-
order	 DNA/RNA	 architecture	 is	 rather	 peculiar,	 given	 that	 its	 stability	 arises	 from	 the	
formation	of	fourfold	symmetrical	G-quartets	(i.e.,	coplanar	and	cyclic	arrangement	of	four	
guanines	 held	 together	 via	 8	 hydrogen	 bonds)	 that	 self-stack	 to	 form	 stable	 DNA/RNA	
structures	(Figure	4).	Quadruplexes	(or	G4s)	are	now	recognized	as	key	players	in	genetics,	
owing	 to	 their	 involvement	 in	 critical	 cellular	 events,	 chief	 among	 them	 replication	 and	
transcription.[28]	 Their	 targeting	 of	 G4s	 by	 ad	 hoc	 chemicals	 (G4-ligands)	 has	 attracted	
considerable	 attention,	 notably	 for	 gaining	 control	 over	 the	 cellular	 processes	 they	 are	
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involved	 in.	 Hundreds	 of	 candidates	 have	 been	 studied	 as	G4-interacting	 compounds,	 the	
overwhelming	majority	of	them	binding	to	the	accessible	external	G-quartet	of	G4s.[29]		
	
	
	
Figure	4.	Schematic	representation	of	a	G-quadruplex	structure	(with	an	emphasis	on	the	chemical	structure	of	
both	guanine	and	G-quartet)	and	its	interaction	with	a	G4-ligand	(upper	panel).	Adapted	from	ref.[30b]	The	smart	
G-quadruplex	 ligand	 PNADOTASQ,	 under	 its	 'open'	 (left)	 and	 'closed'	 conformations	 (right),	 the	 latter	 being	
triggered	by	its	interaction	with	a	G-quadruplex	only.	
	
Given	 the	 fourfold	 symmetry	 of	 this	 privileged	 binding	 site,	 DOTA-based	 G4-ligands	 were	
designed.	 A	 synthetic	 guanine	 was	 inserted	 on	 each	 DOTA	 arm	 to	 allow	 the	 resulting	
compound	 for	 forming	 an	 intramolecular	 synthetic	 G-quartet.	 This	 compound	 named	
DOTASQ	(for	DOTA-templated	synthetic	G-quartet)	uniquely	interacts	with	G4	according	to	a	
biomimetic	process	(i.e.,	the	self-recognition	of	two	G-quartets,	one	from	the	ligand	and	one	
from	the	G4),	thus	being	the	first	prototype	of	biomimetic	G4-ligand.[30]	A	second	generation	
of	DOTASQ	was	reported,	in	which	the	simple	guanines	of	DOTASQ	were	changed	for	peptidic	
nucleic	acid	(PNA)-guanine	monomers,	in	which	the	presence	of	protonable	amine	side-arms	
make	the	resulting	PNADOTASQ	cationic	at	physiological	pH	(Figure	4).	The	wreath	of	cationic	
charges	around	its	intramolecular	G-quartet	governs	and	improves	its	interaction	with	native	
G-quartets	 (surrounded	 by	 negative	 charges	 from	 the	 phosphodiester	 linkages).[31]	
PNADOTASQ	is	a	better	ligand	than	the	neutral	DOTASQ,	for	which	the	presence	of	metal	ion	
(terbium,	 Tb3+)	 was	 mandatory	 to	 trigger	 the	 intramolecular	 G-quartet	 folding.	 This	 was	
evaluated	via	fluorescence	resonance	energy	transfer	(FRET)-melting	assay,	with	DT1/2	=	12.5	
and	1.8	 °C	 for	PNADOTASQ	and	DOTASQ,	 respectively,	versus	9.3	 °C	 for	 the	 [Tb.DOTASQ]3+	
complex.	The	equilibrium	between	the	'open'	(guanines	are	free)	and	'closed'	(guanines	are	
embedded	in	the	intramolecular	G-quartet)	conformations	of	PNADOTASQ	is	actively	and	solely	
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driven	by	its	interaction	with	G4s	(demonstrated	by	NMR),	thus	being	the	first	prototype	of	
smart	G4-ligand.	
	
	
2.	Non-symmetrical	MPAs	
A	 greater	 demand	 for	 multifunctional	 biomolecular	 devices,	 especially	 for	 applications	 in	
chemical	biology,	drug	discovery	and	theranostics,	has	also	led	chemists	to	explore	multiple	
functionalization	of	MPAs	with	different	entities	via	sophisticated	synthetic	strategies.	Some	
examples	illustrating	the	use	of	DOTA	derivatives	as	heteromultifunctional	scaffolds	will	be	
discussed	in	the	next	sections.	
	
2.1	MPAs	with	multiple	functionalities	
To	 further	 exploit	 the	unique	opportunity	offered	by	MPA-based	multimerization,	 Schultz,	
Nazare	and	co-workers	described	an	elegant	chemical	strategy	in	which	they	insert	on	a	DOTA	
platform	 up	 to	 three	 active	 biomolecules	 (collagen	 targeting	 peptides)	 along	 with	 a	
fluorescent	reporter	(i.e.,	the	near-infrared	fluorescent	Cy5.5	dye).[32]	The	use	of	DOTA	mono-
,	di-	or	tri-tert-butyl	ester	in	combination	with	Fmoc/Boc	protecting	group	strategy	enables	a	
facile	and	effective	synthesis	of	these	fluorescently-labeled	multi-peptide	conjugates	through	
sequential	peptide	coupling-type	coupling	reactions	performed	in	solution	(i.e.,	with	DMF	as	
solvent).	 Small-molecules	 targeting	diseased	cartilaginous	 tissues	are	 indeed	scrutinized	as	
promising	molecular	tools	to	remediate	cartilage	breakdown,	responsible	for	osteoarthritis.[33]	
The	 targeting	 of	 one	 of	 the	 cartilage	 constituents,	 here	 the	 type	 II	 collagen,	 by	N-acetyl-
WYRGRL	 (Ac-Trp-Tyr-Arg-Gly-Arg-Leu-OH)	peptides	 being	previously	 established,	 this	 study	
aimed	at	showing	that	the	more	peptidic	arms,	the	better	the	cartilage	targeting,	investigating	
both	 (Ac-WYRGRL)1-DOTA-Cy5.5	 (or	 1TP,	 T	 for	 targeting	 peptide,	 P	 for	 probe)	 and	 (Ac-
WYRGRL)3-DOTA-Cy5.5	(or	3TP)	(Figure	5).	Optical	imaging	investigations	demonstrated	that	
the	 accumulation	 of	 the	 conjugates	 in	 cartilage	 increased	 as	 a	 function	 of	 the	 number	 of	
peptides	 (11.2-fold	 and	 36.6-fold	 increase	 of	 fluorescence	 for	 1TP	 and	 3TP,	 respectively,	
versus	 non-peptide	 but	 Cy5.5-labeled	 DOTA	 control).	 Drug	 multivalency	 thus	 improved	
cartilage	 targeting,	penetration	and	 retention.	 The	versatility	of	 this	 approach	was	 further	
demonstrated	via	the	conjugation	of	both	Ac-WYRGRL	and	pepstatin	A	(JVV-Sta-A-Sta	or	Iva-
Val-Val-Sta-Ala-Sta,	Iva	for	isovaleryl,	Sta	for	statyl,	with	statine	(3S,4S)-4-amino-3-hydroxy-6-
methylheptanoic	 acid)	 on	 DOTA.	 Pepstatin	 A	 is	 a	 known	 inhibitor	 of	 cathepsin	 D,[33]	
responsible	for	glycan	loss-mediated	cartilage	degradation.	The	resulting	conjugates	comprise	
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either	1	Ac-WYRGRL	and	1	pepstatin	A	(1P1I,	P	for	peptide,	I	for	inhibitor),	1	Ac-WYRGRL	and	
3	pepstatin	A	(1P3I)	or	3	Ac-WYRGRL	and	1	pepstatin	A	(3P1I)	(Figure	5).	Though	less	active	in	
vitro	(IC50	=	6.2	and	3.3	nM	for	1P1I	and	3P1I,	respectively,	versus	1.4	nM	for	free	pepstatin	A;	
1P3I	being	insoluble	in	the	condition	of	the	assay),	these	conjugates	were	found	more	active	
than	pepstatin	A	in	ex	vivo	experiments	performed	with	cartilage	explants,	notably	3P1I	that	
maintains	 a	 notable	 inhibitory	 activity	 (18%)	 after	 48	 h.	 These	 results	 demonstrate	 that	
peptide	ligand	multimerization	improves	the	efficiency	of	cartilage	targeting	and,	beyond	this,	
the	strategic	interest	of	DOTA	as	drug	carrier	platform.		
	
	
	
Figure	5.	 Selected	examples	of	multivalent	drug	 carrier	platforms	based	on	DOTA:	 cartilage-targeting	 carrier	
conjugated	to	pepstatin	A	(3P11)	or	the	fluorescent	Cy5.5	dye	(3TP)	(upper	panels),	and	acetyl	prodrug	of	DOTA-
based	 analog	 of	 enterobactin	 conjugated	 to	 the	 fluorescent	 Cy5.5	 dye	 or	 the	b-lactam	 antibiotics	 ampicillin	
(lower	panels).	Counter-ions	(mostly	TFA)	not	shown.	
	
This	 approach	 was	 further	 exploited	 by	 Brönstrup	 and	 co-workers	 through	 the	 use	 of	
multivalent	siderophore-DOTA	conjugates	for	targeting	bacteria.[34]	The	introduction	of	three	
O-acetyl-2,3-dihydroxybenzoic	acid	units	on	the	DOTA	scaffold	via	amide	linkages	made	the	
resulting	conjugate	capable	of	capturing	and	firmly	chelating	iron	(i.e.,	acting	as	a	siderophore	
after	 hydrolysis	 of	 its	 acetate	moieties	 by	 bacterial	 esterases	 and	may	 be	 regarded	 as	 an	
enterobactin	analog).[35]	This	strategy	is	therapeutically	efficient	given	that	coupling	antibiotic	
agents	with	iron-binding	motif	drives	conjugated	xenosiderophores	within	bacteria	through	
their	iron	transportation	machinery.	Here,	the	fourfold	valency	of	DOTA	allows	for	introducing	
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an	additional	functionality	(Figure	5):	either	the	antibiotic	ampicillin	that	results	in	a	conjugate	
with	an	antibacterial	 activity	 lower	against	wild-type	E.	Coli	 (IC50	 =	30.2	versus	 4.3	µM	for	
ampicillin	used	as	control)	but	enhanced	against	enterobactin	receptor-deficient	mutants	(IC50	
=	3.3	versus	6.2	µM	for	ampicillin),	implying	that	DOTA	is	recognized	as	iron	carrier	that	may	
enter	 bacteria	 via	 various	 transporters,	 which	 brings	 significant	 therapeutic	 dividends	 for	
tackling	 resistance	 issues.	 Additionally,	 the	 tris-siderophore-substituted	DOTA	was	 labeled	
with	 a	 Cy5.5	 fluorophore	 leading	 to	 the	 successful	 detection	 of	 bacterial	 infection	 in	 vivo	
through	optical	imaging	in	a	group	of	mice	subcutaneously	injected	with	P.	aeruginosa	(here,	
at	20	µg.kg-1	via	a	monitoring	performed	between	0.6-24	h).	Again,	these	results	highlight	the	
strategic	interest	of	DOTA	as	multivalent	drug	carrier	platform.	
	
	
Figure	6.	Examples	of	biomimetic	(Pyro-DOTASQ)	and	smart	G-quadruplex	ligands	(BioTASQs)	based	on	the	C-
functionalized	 DOTA	 platform	 (upper	 panel).	 Schematic	 representation	 of	 the	 use	 of	 BioTASQ	 to	 fish	 G-
quadruplexes	 out	 from	 human	 cells	 via	 an	 affinity	 pull-down	 strategy	 (lower	 panel).	 Adapted	 from	 ref.[38]	
copyright	(2019),	with	permission	from	Oxford	University	Press.	
	
2.2	C-functionalization	of	MPAs	
For	some	applications,	the	chemical	differentiation	and	orthogonal	derivatization	of	the	four	
acetic	acid	pendant	arms	of	a	DOTA	platform	is	not	relevant	or	suited	to	obtain	targeted	multi-
component	conjugates.	In	this	context,	another	way	for	introducing	an	additional	functionality	
on	DOTA,	while	keeping	the	global	symmetry	of	the	conjugate,	 is	to	chemically	modify	the	
DOTA	scaffold	itself.	The	C-functionalization	of	cyclen	has	been	reported	as	a	way	to	introduce	
an	aminomethyl	appendage	on	cyclen	poised	to	be	conjugated	through	conventional	peptide-
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type	coupling	chemistry.[36]	This	approach	was	exploited	to	insert	a	pyrene	moiety	on	DOTASQ	
(vide	 supra)	 for	 making	 the	 resulting	 terbium	 complex	 [Tb.Pyro-DOTASQ]3+	 (Figure	 6),	 a	
luminescent	ligand	readily	immobilizable	on	graphene	surface.[37]	The	insertion	of	pyrene	was	
found	to	improve	the	G4-binding	properties	of	the	complex	(evaluated	via	FRET-melting	assay,	
with	DT1/2	=	15.3	and	9.3	°C	for	[Tb.Pyro-DOTASQ]3+	and	[Tb.DOTASQ]3+,	respectively),	likely	
due	to	its	steric	hindrance	that	might	facilitate	the	spatial	orientation	of	the	four	guanine	arms	
on	the	same	side	of	the	DOTA	scaffold.	Upon	irradiation	at	308	nm,	the	complex	was	found	to	
efficiently	sense	the	presence	of	G4s	(with	a	4-fold	enhancement	of	the	luminescence	signal	
at	545	nm	in	presence	of	10	molar	equivalents	G4s,	versus	no	modifications	with	duplex-DNA).	
The	C-functionalization	 strategy	was	also	 implemented	 to	add	a	biotin	 tag	on	DOTASQ,	 in	
order	to	allow	the	resulting	BioTASQ	for	being	used	as	a	bait	for	capturing	G4-DNA/RNA	from	
human	 cells.[38]	 Thanks	 to	 the	 well-known	 biotin/streptavidin	 affinity	 purification	 system,	
BioTASQ	 efficiently	 pulls	 down	 G4-RNA	 from	 living	 human	 cells,	 prior	 to	 sequencing	 for	
characterizing	 isolated	G4-RNA	sequences.	Two	biotin	appendages	were	 introduced	(biotin	
per	se,	and	PEG4-biotin,	for	BioTASQ	v.1	and	v.2,	respectively,	Figure	6),	which	in	both	cases	
decreases	its	affinity	of	G4	in	vitro	(evaluated	via	FRET-melting	assay,	with	DT1/2	=	2.4	and	0.4	
°C	for	BioTASQ	v.1	and	v.2,	respectively	versus	12.5	°C	for	the	parent	PNADOTASQ),	likely	due	
to	an	intramolecular	interaction	between	biotin	and	guanine	moieties.	The	interaction	with	
streptavidin-coated	 particles	 allows	 for	 tackling	 this	 issue	 (hijacking	 biotin)	 and	 makes	
BioTASQs	 capture	 efficiently	 G4s	 (G4-RNA	 precipitation,	 G4RP)	 subsequently	 identified	 by	
sequencing	(G4RP-seq	protocols).[39]	This	technique,	derived	from	the	Chem-seq	method,[40]	
has	 not	 only	 allowed	 for	 confirming	 the	 transient	 existence	 of	 G4s	 in	 functional	 cells	
(highlighting	their	transient	formation)	but	also	for	assessing	the	variations	in	G4	landscapes	
upon	G4-ligand	treatment.	
	
2.3	MPAs	and	higher-order	chemical	architectures	
MPAs	were	also	used	as	platforms	for	building	higher-scale	suprastructures.	As	an	example,	
Yu	and	co-workers	synthesized	cyclen-based	cationic	lipopolymers	to	serve	as	gene	vectors.[41]	
The	intracyclic	nitrogen	atoms	of	the	cyclen	were	used	as	hydrophilic	headgroups	whereas	the	
acetate	 arms	 were	 conjugated	 to	 small	 lipids	 via	 ring-opening	 polymerization	 to	 build	
amphiphilic	 polymers	 (Figure	 7).	 They	 display	 enhanced	 transfection	 efficiency	 (TE)	 and	
cellular	 uptake,	 notably	 thanks	 to	 the	 "proton	 sponge	 effect"[42]	 that	 is	 based	 on	 the	
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protonation	 of	 the	 gene	 vector	within	 the	 endosomes,	which	 favors	 osmotic	 swelling	 and	
endosomal	rupture	to	deliver	the	nucleic	acid	partners.	The	chemical	nature	of	cyclen	allows	
for	the	formation	of	linear	polymers	only,	with	a	rather	low	degree	of	polymerization	(MW	<	
5000).	These	amphiphilic	compounds	self-assemble	in	solution	into	nanometer-size	micellar	
structures	(critical	micelle	concentration:	0.2	mg/mL;	average	micelle	size	=	300	nm).		These	
polymers,	which	displayed	 low	 intrinsic	 toxicity,	were	used	to	condensate	DNA	(with	a	2.8	
polymer/DNA	weight	ratio,	here	the	pGL-3	plasmid	coding	for	luciferase	as	reported	gene)	and	
transfect	 cancer	 cells	 with	 a	 higher	 TE	 (14-fold)	 than	 that	 of	 commercially	 available	
transfection	 agents	 (polyethylenimine,	 PEI).[3a]	 Of	 note,	 the	 MPA-based	 gene	 delivery	
approach	was	thoroughly	investigated	with	cyclen[43]	but	also	with	alternative	MPAs	such	as	
[12]aneN3[44]	or	TACN,[45]	highlighting	again	the	great	versatility	of	this	family	of	macrocycles.		
	
	
	
Figure	7.	Selected	examples	of	cyclen-based	high-order	chemical	architectures:	amphiphilic	polymer	for	gene	
delivery	(upper	panel);	on-bead	structure	of	tri-peptoid-DOTA	molecule	for	screening	and	discovering	novel	and	
multivalent	theranostic	agents	(central	panel);	and	uranyl-organic	framework	in	which	DOTA	acts	as	a	"square	
assembler"	(lower	panel).	
	
Another	approach	was	reported	by	Udugamasooriya	and	co-workers	in	which	they	use	DOTA	
to	build	on-bead	combinatorial	libraries	of	DOTA-peptoid	conjugates,[46]	aimed	at	being	used	
for	screening	and	discovering	novel	and	multivalent	theranostic	agents.	To	this	end,	one	arm	
	 14	
of	the	DOTA	was	used	to	immobilize	the	construct	on	TentaGel	beads	(300	µM	diameter)	via	
a	 short	 Met-(Nmea-Gly)-bAla	 linker	 (Met	 for	 methionine,	 Nmea-Gly	 for	 N-(2-
methoxyethyl)glycine	and	bAla	for	b-alanine),	the	three	other	arms	used	to	introduce	6-mer	
peptoid	units	through	PEG-type	linkers	of	various	lengths	(Figure	7).	This	approach,	so	called	
of	split-pool	synthesis,	allowed	for	generating	a	library	that	amounts	to	>150	000	compounds	
in	 a	 straightforward	 and	 efficient	 manner	 also	 exploiting	 the	 effectiveness	 of	 microwave	
(MW)-assisted	solid-phase	peptide	synthesis	protocols	(overall	yields	>80%).	Hudson	and	co-
workers	also	thoroughly	investigated	the	chemistry	of	MPA-peptide	conjugates,	developing	a	
straightforward	access	via	either	MPA	peralkylation	strategies	 implemented	with	cyclen	to	
produce	DOTA-type	conjugates[47]	(but	also	TACN	and	cyclam	derivatives)[48]	or	click	chemistry	
approach	 performed	 with	 non-symmetrical	 DOTA	 derivatives	 and	 based	 on	 the	 prior	
incorporation	of	a	 terminal	alkyne	 into	the	side-chain	of	 tyrosine	residue(s)	 (i.e.,	propargyl	
ether	moiety).[49]	Finally,	DOTA	was	also	used,	yet	more	anecdotally,	as	a	"square	assembler"	
in	metal-organic	frameworks	(MOF):[50]	in	this	assembly,	DOTA	does	not	chelate	metal	within	
its	cavity	but	 is	surrounded	by	four	uranyl	U(IV)	cations	 (UO22+),	 likely	due	to	the	excess	of	
metal	 (i.e.,	 4	mol.	 equiv.),	which	 connected	 the	matrix	 via	 oxalato	 bridges	 (Figure	 7).	 The	
obtained	crystal	structure	confirmed	the	square	conformation	of	DOTA,	which	provides	a	MOF	
with	5	x	8	Å	pores.	Cyclen	was	also	used	to	assemble	suprastructures	such	as	carbon	dots	(CDs)	
via	a	MW-assisted	condensation	reaction	with	citric	acid	followed	by	a	carbonization	step.[51]	
The	 obtained	 blue-emitting	 CDs	were	 further	 used	 to	 coordinate	 europium	 (Eu3+)	 ions	 to	
construct	a	ratiometric	fluorescent	probe	for	tetracyclin	detection.	
	
3.	Other	types	of	MPA	platforms		
While	 most	 of	 the	 examples	 of	 multivalent	 bioconjugates	 reported	 in	 the	 literature	 (and	
discussed	above)	are	built	around	a	cyclen	platform,	 the	use	of	other	MPAs	has	also	been	
exploited.	 They	 offer	 different	 topological	 and	 functional	 possibilities	 and	 their	 unique	
chemistry	is	suited	to	construct	original	molecular	devices	with	new	applications,	notably	in	
the	chemical	biology	area.		
	
3.1	Sarcophagine,	NOTA	and	RGD	multimerization	
Other	MPAs	than	the	cyclen/DOTA	system	were	used	as	molecular	platforms:	Li,	Conti	and	co-
workers	 have	 for	 instance	 developed	 a	 multifunctional	 sarcophagine	 template,	 aimed	 at	
tackling	in	vivo	stability	of	the	64Cu/MPA	complexes.	The	two	pendant	amine	groups	of	this	
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bicyclic	MPA	were	derivatized	to	allow	for	the	grafting	of	two	c(RGDyC)	units	via	maleimide	
(Mal)	 linkers.	 The	 copper	 complexes	 of	 the	 resulting	 Mal2Sar-RGD2	 (Figure	 8)	 showed	
improved	 in	vivo	stability	and	better	kinetics	as	compared	to	DOTA-c(RGDyC)	conjugates	in	
human	glioma	tumors.[52]		
	
	
	
Figure	 8.	 Selected	 examples	 of	mulitvalent	 bioconjugates	 based	 on	 different	MPAs	 (including	 sarcophagine,	
TACN,	 cyclen,	 cyclam	 and	 cyclal)	 and	 phosphonate	 derivatives	 of	 tetraazamacrocycles	 used	 as	 inhibitors	 of	
protein	tyrosine	phopshatases).		
	
A	 similar	 c(RGDyC)	multimerization	approach	was	 followed	by	Sun	and	co-workers	using	a	
1,4,7-triazacyclonane-1,4,7-triacetic	acid	(or	NOTA)	platform,	surrounded	by	1	to	3	c(RGDyC)	
units	 (named	H31,	H32	 and	H33,	 respectively).[53]	The	multimeric	conjugates	were	 found	 to	
have	better	avb3	binding	in	vitro	than	the	monomeric	control	(IC50	=	171,	44	and	15	nM	for	
H31,	H32	and	H33,	respectively,	Figure	8)	and	the	c(RGDyC)	itself	(IC50	=	204	nM),	along	with	
better	 in	 vivo	 properties	 (higher	 stability,	 imaging	 signal	 amplification).	 These	 two	 studies	
brightly	highlight	and	confirm	again	the	aforementioned	positive	effect	of	RGD	multivalency	
on	both	binding	affinity	and	specificity	and	imaging	signal	amplification.	
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3.2	Cyclam,	cyclal	and	phosphatase	inhibitors	
Vovk,	Kukhar	and	co-workers	reported	on	the	use	of	1,4,8,11-tetraazacyclotetradecane	(or	
cyclam)	to	assemble	effective	inhibitors	of	T-cell	protein	tyrosine	phosphatases	(TC-PTP),	an	
enzyme	involved	in	the	development	of	type	I	diabetes.[54]	Known	TC-PTP	inhibitors	include	
aromatic	compounds	with	phosphonic	groups,	notably	a,a-difluoro-b-ketophosphonates	that	
poison	 the	 enzyme	 active	 site.[55]	 Cyclam	 but	 also	 cyclen	 and	 1,4,8,12-
tetraazacyclopentadecane	(or	cyclal)	were	used	to	bring	together	four	ketophosphonate-type	
arms	 within	 a	 single	molecular	 scaffold	 (Figure	 8).	 Direct	N-alkylation	 of	 cyclam	with	 the	
corresponding	 a,a-difluoro-b-ketophosphonate-functionalized	 benzyl	 bromide	 failed	 to	
provide	the	desired	tetra-N-substituted	derivative	 in	an	effective	manner	(yield	<10%	after	
purification	 by	 column	 chromatography	 on	 silica	 gel).	 An	 alternative	 procedure	 involving	
alkylation	 of	MPA	with	methyl	 3-bromomethylbenzoate,	 followed	 by	 cerium(III)-mediated	
reaction	of	ester	moieties	with	LiCF2P(O)(OEt)2	and	final	deprotection	of	phosphonate	ethyl	
esters	with	bromotrimethylsilane	provided	the	desired	multivalent	PTP	inhibitors	 in	decent	
overall	yields	(6-24%	for	the	three-step	procedure).	Both	the	cyclen-	(2)	and	cyclam-based	(3)	
conjugates	prove	more	efficient	than	the	cyclal	conjugate	(4,	with	IC50	=	75,	590	and	91	nM	
for	cyclam-,	cyclen-	and	cyclal-based	derivatives,	respectively,	versus	>100	µM	for	monomeric	
ketophosphonate	used	as	control),	with	a	better	ability	to	discriminate	between	various	PTP,	
notably	the	closely	related	PTP1B,	a	negative	regulator	of	insulin	signaling	(with	IC50	=	1.08,	
4.04	and	1.48	µM	for	cyclam-,	cyclen-	and	cyclal-based	derivatives,	respectively).	
	
3.3	TACN	and	DNA	junctions	
1,4,7-triazacyclonane	(or	TACN)	was	also	exploited	to	benefit	from	its	C3-symmetry	suited	to	
the	 construction	 of	 chemicals	 targeting	 threefold	 symmetrical	 targets.	 Three-way	 DNA	
junctions	(TWJ)	are	Y-shaped,	higher-order	DNA	structure	at	the	heart	of	which	a	threefold	
symmetrical	 cavity	 is	 formed	 (the	 branch	 point),	 ideally	 suited	 to	 accommodate	 C3-
symmetrical	ligands.[56]	DNA	junctions	might	arise	ahead	of	the	replication	fork,	as	a	way	to	
relax	helical	stress	that	originates	in	the	translocation	of	the	replication	machinery	along	the	
duplex.	If	not	properly	processed	(by	helicases),	these	structures	act	as	impediments	to	DNA	
transactions,	forcing	the	fork	to	stall	or	collapse.[57]	Stabilization	of	TWJ	by	ad	hoc	chemicals	
(TWJ-ligands)	 is	 thus	 a	 new	 strategy	 to	 create	 DNA	 damages	 and	 trigger	 cell	 death	 in	
proliferating	 cancer	 cells.[58]	 A	 TACN	 scaffold	 surrounded	by	 three	2-methylquinoline	 arms	
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(TACN-Q)	(Figure	8)	was	shown	to	stabilize	folded	TWJ	(evaluated	by	FRET-melting	assay,	with	
DT1/2	 =	 3.8	 °C)[59]	 but,	 more	 importantly,	 promote	 the	 formation	 of	 TWJ	 from	 separated	
strands	 (by	 polyacrylamide	 gel	 and	 TWJ-screen	 experiments).[60]	 TACN-Q	 also	 exhibit	
promising	anticancer	activity	(IC50	=	10.6	µM	against	melanoma	cells).		
	
4.	Conclusions		
Through	these	selected	examples,	it	is	evident	that	the	scope	of	applications	of	MPAs	goes	
far	beyond	the	limited	roles	of	complexing	agents	for	metal	cations	(especially	radiometals).	
As	demonstrated	here,	MPAs	are	highly	versatile	molecular	tools	that	prove	efficient	in	many	
areas,	from	material	science	to	chemical	genetics.	Besides	their	roles	as	multivalent	molecular	
platforms,	MPAs	can	find	other	uses	that	are	yet	beyond	the	strict	context	of	this	review	but	
are	 also	 invaluable	 to	 further	 substantiate	 their	 versatility.	 For	 instance,	 different	 MPA	
moieties	have	been	incorporated	within	the	core	structure	of	complex	bioactive	compounds	
(Figure	9)	either	as	water-solubilizing	appendages	(which	also	favors	the	renal	clearance	of	
LLP2	peptide	that	targets	very-late	antigen	4	(VLA-4)	overexpressed	on	the	surface	of	cancer	
cells),[61]	or	as	ATP-binding	moieties	(both	TACN	and	cyclen	were	introduced	on	a	dual	kinase	
(EGFR/HER2)	 inhibitors)[62]	 in	 light	of	pioneering	works	from	Lehn	and	co-workers	on	anion	
receptor	polyazamacrocycles.[63]	MPAs	have	also	been	used	for	chelating	in	situ	metals:	this	
strategy	allows	for	modulating	abnormal	metal	metabolism	such	as	in	Alzheimer’s	disease	in	
which	 a	 high	 copper	 concentration	 triggers	 neuronal	 toxicity	 favoring	 the	 formation	 of	
pathogenic	b-amyloid	plaques	and	reactive	oxygen	species	(ROS).	Derivatives	of	TACN,[64]	of	
cyclam	and	cyclen[65]	were	studied,	the	latter	being	conjugated	with	the	b-sheet	breaker	KLVFF	
peptide[66]	or	with	silica	nanoparticles.[67]		
MPAs	 have	 also	 been	 embedded	 as	 bioactive	 components	 per	 se,	 the	 most	 brilliant	
example	being	certainly	AMD3100:[68]	this	bis-cyclam	derivative	is	used	as	an	antagonist	of	
CXCR4	receptors,	 initially	developed	as	an	anti-HIV	agent	and	subsequently	repurposed	for	
the	 mobilization	 of	 hematopoietic	 stem	 cells	 in	 cancer	 patients,	 now	 commercialized	 as	
Mozobil®	 (plerixafor).[69]	 AMD3100	 was	 also	 studied	 for	 its	 ability	 to	 alter	 the	 copper	
metabolism	 in	Alzheimer’s	disease	(vide	supra)[70]	and	as	possible	anti-malaria	agent.[71]	To	
improve	the	pharmacological	properties	of	AMD3100,	many	derivatives	have	been	designed	
and	synthesized	(Figure	9),	in	which	the	core	structure	of	cyclam	was	changed	for	1,4-dioxa-	
or	1,4-dithia-8,11-diazacyclotetradecane,[72]	or	for	side-	or	cross-bridged	cyclams[73]	(also	used	
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for	building	original	antimalarial	agents)[74]	thus	expanding	the	chemistry	of	MPAs.	Similarly,	
cyclen-	 and	 cyclam-based	 MPAs	 were	 investigated	 to	 fight	 against	 the	 parasitic	 diseases	
leishmaniasis,	and	it	was	found	that	2	metal	complexes	(out	of	44	tested	compounds),	i.e.,	the	
iron(II)	 and	 manganese(II)	 complexes	 of	 a	 bisbenzylcyclen	 derivative,	 displayed	 the	 most	
promising	properties	as	antileishmanial	agents.[75]	
	
	
	
Figure	9.	Selected	examples	of	compounds	bearing	one	or	two	MPAs	that	behave	as	bioactive	moieties	per	se.	
	
These	examples	further	nurture	the	view	whereby	MPAs	are	far	more	versatile	than	initially	
anticipated.	We	are	convinced	that	the	best	is	still	to	come,	with	new	generations	of	chemists	
eager	and	poised	to	decompartmentalize	chemical	fields	to	make	the	best	use	of	the	portfolio	
of	advanced	molecular	tools	at	their	disposal.	This	will	provide	genuine	new	opportunities	and	
open	brand	new	chemical	landscapes	that	are	still,	at	present,	beyond	imagining.		
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Graphical	abstract	
	
	
No	metal,	no	cry!	Macrocyclic	polyamines	(MPAs)	are	important	chelating	agents	for	cations,	anions	and	neutral	
molecules.	Most	common	compounds	such	as	cyclen	and	DOTA	are	inseparable	from	great	advances	in	the	field	
of	contrast	agents	for	magnetic	resonance	or	PET/SPECT	imaging.	Their	unique	topological	and	physicochemical	
properties	make	them	also	attractive	multivalent	molecular	platforms	for	applications	that	go	far	beyond	the	
conventional	metal	chelation.	The	key	topics	discussed	in	this	review	are	the	use	of	MPAs	as	molecular	platforms	
for	applications	in	material	chemistry,	medicinal	chemistry	and	chemical	biology.	
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